Breaking Finance News

A statement released earlier today by Leerink Swann about Bluebird Bio Inc (NASDAQ:BLUE) bumps the target price to $80.00

Just yesterday Bluebird Bio Inc (NASDAQ:BLUE) traded -0.47% lower at $57.92. Bluebird Bio Inc’s 50-day moving average is $63.52 and its 200-day moving average is $50.81. The last stock price is up 28.40% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,584,592 shares of BLUE traded hands, up from an average trading volume of 1,147,150

Leerink Swann bumped up the target of Bluebird Bio Inc (NASDAQ:BLUE) to $80.00 stating a potential upside of 0.38%.

Recent Performance Chart

Bluebird Bio Inc (NASDAQ:BLUE)

Bluebird Bio Inc has 52 week low of $35.37 and a 52 week high of $99.70 and has a market capitalization of $0.

In addition to Leerink Swann reporting its stock price target, a total of 14 brokerages have issued a ratings update on the company. The average stock price target is $89.07 with 6 brokerages rating the stock a strong buy, 6 brokerages rating the stock a buy, 3 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Bluebird Bio Inc (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *